BSE Live
Apr 02, 16:01Prev. Close
7852.75
Open Price
7852.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 02, 15:47Prev. Close
7852.00
Open Price
7790.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
7827.50 (150)
| Key Financial Ratios of AstraZeneca Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 28.90 | 21.80 | 10.40 | 8.00 | 2.10 | |
| Diluted EPS (Rs.) | 28.90 | 21.80 | 10.40 | 8.00 | 2.10 | |
| Cash EPS (Rs.) | 36.32 | 27.75 | 16.26 | 14.35 | 9.07 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 145.78 | 120.32 | 98.77 | 89.15 | 62.41 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 145.78 | 120.32 | 98.77 | 89.15 | 62.41 | |
| Dividend / Share(Rs.) | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 332.72 | 291.32 | 228.40 | 217.48 | 225.49 | |
| PBDIT/Share (Rs.) | 53.48 | 35.04 | 23.42 | 20.53 | 9.28 | |
| PBIT/Share (Rs.) | 46.04 | 29.07 | 17.52 | 14.20 | 2.31 | |
| PBT/Share (Rs.) | 45.59 | 29.07 | 17.52 | 14.20 | 2.31 | |
| Net Profit/Share (Rs.) | 28.88 | 21.78 | 10.36 | 8.02 | 2.10 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 16.07 | 12.02 | 10.25 | 9.44 | 4.11 | |
| PBIT Margin (%) | 13.83 | 9.97 | 7.67 | 6.52 | 1.02 | |
| PBT Margin (%) | 13.70 | 9.97 | 7.67 | 6.52 | 1.02 | |
| Net Profit Margin (%) | 8.68 | 7.47 | 4.53 | 3.68 | 0.93 | |
| Return on Networth / Equity (%) | 19.81 | 18.10 | 10.49 | 8.99 | 3.37 | |
| Return on Capital Employed (%) | 30.36 | 23.99 | 17.27 | 15.76 | 3.34 | |
| Return on Assets (%) | 10.22 | 9.69 | 5.62 | 4.82 | 1.29 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover Ratio (%) | 117.76 | 129.63 | 123.98 | 130.85 | 138.94 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.66 | 1.56 | 1.55 | 1.32 | 1.08 | |
| Quick Ratio (X) | 1.15 | 1.11 | 1.00 | 1.02 | 0.77 | |
| Inventory Turnover Ratio (X) | 5.04 | 6.17 | 5.05 | 9.42 | 7.35 | |
| Dividend Payout Ratio (NP) (%) | 3.46 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 2.75 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 96.54 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 97.25 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 5,726.36 | 4,822.45 | 2,190.33 | 2,236.17 | 2,814.79 | |
| EV/Net Operating Revenue (X) | 6.88 | 6.62 | 3.84 | 4.11 | 4.99 | |
| EV/EBITDA (X) | 42.83 | 55.06 | 37.42 | 43.56 | 121.38 | |
| MarketCap/Net Operating Revenue (X) | 7.19 | 6.86 | 4.06 | 4.33 | 5.13 | |
| Retention Ratios (%) | 96.53 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 16.41 | 16.61 | 9.38 | 10.55 | 18.53 | |
| Price/Net Operating Revenue | 7.19 | 6.86 | 4.06 | 4.33 | 5.13 | |
| Earnings Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
12.02.2026
01.02.2026
12.11.2025
AstraZeneca Standalone September 2025 Net Sales at Rs 559.09 crore, up 37.03% Y-o-Y
10.11.2025
12.11.2025
AstraZeneca Standalone September 2025 Net Sales at Rs 559.09 crore, up 37.03% Y-o-Y
06.06.2025
AstraZeneca Standalone March 2025 Net Sales at Rs 480.48 crore, up 25.39% Y-o-Y
17.02.2025
AstraZeneca Standalone December 2024 Net Sales at Rs 440.29 crore, up 43.98% Y-o-Y
21.11.2024
AstraZeneca Standalone September 2024 Net Sales at Rs 408.00 crore, up 31.16% Y-o-Y
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth